Bolstering a Resurgence in Novel Approaches to Target Underlying Pathology, Address Disease Heterogeneity & Restore Hope in a More Transformative Wave of ALS & FTD Therapies
United ALS Biotech, Pharma & Academia to Accelerate the Next Generation of ALS & FTD Therapeutics
Strategic moves across the sector—from Eli Lilly's Alchemab-backed ALS expansion to BMS and insistro's genetically driven collaboration and Clene Nanomedicine's regulatory-stage program—underscore the ALS community’s continued commitment to advancing impactful therapies, even in the face of clinical setbacks.
With over 475 therapies in development, and 157 active or enrolling trials, and more than 350 companies actively working in ALS, and a global ALS market projected to grow from USD 667.3M in 2023 to USD 987.6M by 2030, confidence is returning. Learnings, fuelled by stronger mechanistic hypotheses, and more resilient translational strategies, spanning TDP 43 loss and gain of function biology, cryptic exon regulation, neuroinflammatory pathways, and human relevant iPSC and 3D models, the ALS community is leveraging these lessons to build smarter, more predictive programs.
Uniting 100+ senior experts across discovery, translational research, clinical development, regulatory science, investment, and patient advocacy, 30+ speakers from AbbVie, AskBio, Biogen, Eli Lilly, Novartis, QurAlis, Prilenia Therapeutics, Mitsubishi Tanabe Pharma, uniQure, ROME Therapeutics, Everything ALS, Sanofi, and more, this is the definitive forum restored hope across the ALS & FTD community.
Hear from the 2026 Speakers:
The summit will include, as in prior years, pertinent presentations related to current ALS drug development programs. It is a forum for open scientific, clinical and nonclinical exchanges of experiences in ALS drug development. Anyone developing drugs for ALS, can benefit from this focused conference and learn from others in the field.
Given the rapidly changing landscape drug development and regulatory perspectives, the drug development community will be strongest and most resilient when working together to develop meaningful new therapeutics for a devastating disease such as ALS.
Irina Antonijevic, Chief Medical Officer, Trace Neuroscience Inc.
Engaging with leading experts in a scientific field often sparks the kind of intellectual energy that gives rise to groundbreaking ideas.
George Apostol, Head Clinical Development, uniQure
This conference is a great opportunity for industry and academic experts to discuss the recent advances and remaining key challenges in the field.
Kelly Glajch, Scientific Director, Rare Neurology- Neuroscience Therapeutic Area Unit, Takeda
Accelerating Transformative Drugs for ALS & FTD Patients
Divide & Conquer
Teams came together and uncovered more insights as they divided and conquered across our two expertly curated tracks.
Explore the 2026 Full Event Guide
- 30+ World Class Speakers with Cutting Edge Insights
- 10+ Hours of Face-to-Face Networking Opportunities
- 3 Days of Unmissable Data-Driven Content
- 2 Dedicated Tracks of Content Spanning Discovery to Access for the Whole Team
Meet the 2026 Speakers
Official 2026 Partners
Attending Companies Included
Explore Related Events
Explore the 2026 Agenda
Dive into 2 tracks, spanning discovery – clinical development and access, 3 preconference day workshops and 30+ expert speakers shaping the future of ALS & FTD
Partner With Us
Showcase your solutions, connect with decision makers, and position your company as the go-to provider in neuromuscular and neurodegenerative research
Join Biopharma Experts
Network with pharma, biotech, diagnostics, academia, consortia, and patient voices driving real-world adoption